184 related articles for article (PubMed ID: 38300458)
1. How Do We Manage Chronic Lymphocytic Leukemia in India.
Karunakaran P; Jain N; Lad DP
Curr Hematol Malig Rep; 2024 Apr; 19(2):56-64. PubMed ID: 38300458
[TBL] [Abstract][Full Text] [Related]
2. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
Geethakumari PR; Awan F
Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
[TBL] [Abstract][Full Text] [Related]
4. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
5. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
Shadman M
JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212
[TBL] [Abstract][Full Text] [Related]
7. BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.
Spaargaren M; de Rooij MF; Kater AP; Eldering E
Oncogene; 2015 May; 34(19):2426-36. PubMed ID: 24954503
[TBL] [Abstract][Full Text] [Related]
8. BTK Inhibitors in Chronic Lymphocytic Leukemia.
Gaballa S; Pinilla-Ibarz J
Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
[TBL] [Abstract][Full Text] [Related]
9. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
Woyach JA; Bojnik E; Ruppert AS; Stefanovski MR; Goettl VM; Smucker KA; Smith LL; Dubovsky JA; Towns WH; MacMurray J; Harrington BK; Davis ME; Gobessi S; Laurenti L; Chang BY; Buggy JJ; Efremov DG; Byrd JC; Johnson AJ
Blood; 2014 Feb; 123(8):1207-13. PubMed ID: 24311722
[TBL] [Abstract][Full Text] [Related]
10. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Thompson PA; Burger JA
Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
[TBL] [Abstract][Full Text] [Related]
11. Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.
Sinha S; Boysen J; Nelson M; Secreto C; Warner SL; Bearss DJ; Lesnick C; Shanafelt TD; Kay NE; Ghosh AK
Clin Cancer Res; 2015 May; 21(9):2115-26. PubMed ID: 25673699
[TBL] [Abstract][Full Text] [Related]
12. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
Small S; Ma S
Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
[TBL] [Abstract][Full Text] [Related]
13. Practical management of chronic lymphocytic leukemia with acalabrutinib.
Kuss B; Nagarajan C; Hsieh WS; Cheah CY
Leuk Lymphoma; 2022 Dec; 63(12):2785-2794. PubMed ID: 35852229
[TBL] [Abstract][Full Text] [Related]
14. Novel treatments for chronic lymphocytic leukemia and moving forward.
Brown JR; Porter DL; O'Brien SM
Am Soc Clin Oncol Educ Book; 2014; ():e317-25. PubMed ID: 24857119
[TBL] [Abstract][Full Text] [Related]
15. Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.
Wiedmeier-Nutor J; Leis J
Curr Treat Options Oncol; 2022 Jun; 23(6):904-919. PubMed ID: 35435617
[TBL] [Abstract][Full Text] [Related]
16. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Tran PN; O'Brien S
Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
[TBL] [Abstract][Full Text] [Related]
17. A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.
Robak P; Robak T
Curr Med Chem; 2012; 19(31):5294-318. PubMed ID: 22830347
[TBL] [Abstract][Full Text] [Related]
18. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
19. [Molecular pathogenesis and treatment of chronic lymphocytic leukemia].
Suzuki R
Rinsho Ketsueki; 2021; 62(8):1085-1093. PubMed ID: 34497195
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Double-Refractory Chronic Lymphocytic Leukemia-An Unmet Clinical Need.
Zygmunciak P; Robak T; Puła B
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
